Wednesday, July 8, 2026

Drug profile · INN

amoxapine

amoxapine (AMOXAPINE) is a norepinephrine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — amoxapine
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.89

Quick answer

amoxapine (AMOXAPINE) is a norepinephrine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN amoxapine
Brand AMOXAPINE
Mechanism Norepinephrine transporter inhibitor
Target Dopamine receptor
Route ORAL
Formulation TABLET

Mechanism of action

Norepinephrine transporter inhibitor

Primary target: Dopamine receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. cabergoline Dopamine D2 receptor agonist
  4. chlorpromazine hydrochloride D2-like dopamine receptor antagonist
  5. clozapine Serotonin 2a (5-HT2a) receptor antagonist
  6. droperidol D2-like dopamine receptor antagonist

Frequently asked questions

What is amoxapine?

amoxapine (AMOXAPINE) is a norepinephrine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for amoxapine?

AMOXAPINE is a marketed brand name for amoxapine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of amoxapine?

amoxapine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.